PGEN - Precigen interim early-stage data on AML therapy shows 50% objective response rate

Precigen's (NASDAQ:PGEN) acute myeloid leukemia candidate PRGN-3006 UltraCAR-T demonstrated an objective response rate of 50% based on six patients. In the lymphodeletion cohort, there were two complete responses at the two lowest dose levels. In the same cohort, stable disease for more than three months was seen in 33% (three of nine) patients. No dose-limiting toxicities or neurotoxicity was observed. Shares are down ~2.2% in after-hours trading. The data was presented at the American Society of Hematology Annual Meeting. #ASH2021 Read about a phase 1 trial of the company's hematological and solid tumors candidate, PRGN-3007.

For further details see:

Precigen interim early-stage data on AML therapy shows 50% objective response rate